AU2003257473A1 - Modified amino acid for the inhibition of platelet aggregation - Google Patents

Modified amino acid for the inhibition of platelet aggregation

Info

Publication number
AU2003257473A1
AU2003257473A1 AU2003257473A AU2003257473A AU2003257473A1 AU 2003257473 A1 AU2003257473 A1 AU 2003257473A1 AU 2003257473 A AU2003257473 A AU 2003257473A AU 2003257473 A AU2003257473 A AU 2003257473A AU 2003257473 A1 AU2003257473 A1 AU 2003257473A1
Authority
AU
Australia
Prior art keywords
platelet aggregation
amino acid
modified amino
inhibition
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003257473A
Other languages
English (en)
Inventor
Moise Azria
Simon David Bateman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2003257473A1 publication Critical patent/AU2003257473A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2003257473A 2002-07-17 2003-07-16 Modified amino acid for the inhibition of platelet aggregation Abandoned AU2003257473A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39689802P 2002-07-17 2002-07-17
US60/396,898 2002-07-17
PCT/EP2003/007739 WO2004006907A1 (en) 2002-07-17 2003-07-16 Modified amino acid for the inhibition of platelet aggregation

Publications (1)

Publication Number Publication Date
AU2003257473A1 true AU2003257473A1 (en) 2004-02-02

Family

ID=30116066

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003257473A Abandoned AU2003257473A1 (en) 2002-07-17 2003-07-16 Modified amino acid for the inhibition of platelet aggregation

Country Status (12)

Country Link
US (3) US20060106110A1 (enExample)
EP (1) EP1556027B1 (enExample)
JP (1) JP4541884B2 (enExample)
CN (1) CN1668290B (enExample)
AT (1) ATE538782T1 (enExample)
AU (1) AU2003257473A1 (enExample)
BR (1) BR0312712A (enExample)
CA (1) CA2492378C (enExample)
ES (1) ES2379949T3 (enExample)
PT (1) PT1556027E (enExample)
TW (1) TW200403052A (enExample)
WO (1) WO2004006907A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007521232A (ja) 2003-08-08 2007-08-02 アブジェニックス・インコーポレーテッド 副甲状腺ホルモン（ｐｔｈ）に対する抗体およびその使用
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
EP1907571B1 (en) 2005-06-15 2017-04-26 Complete Genomics Inc. Nucleic acid analysis by random mixtures of non-overlapping fragments
CN101627011A (zh) * 2005-09-19 2010-01-13 爱密斯菲尔科技公司 N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形
US8895777B2 (en) 2006-08-31 2014-11-25 Emisphere Technologies Inc Compounds and compositions for delivering active agents
PL2059260T3 (pl) * 2006-08-31 2014-03-31 Novartis Ag Kompozycja farmaceutyczna obejmująca hGH do dostarczania doustnego
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
US20110207693A1 (en) * 2010-02-24 2011-08-25 Emisphere Technologies, Inc. Oral B12 Therapy
RU2504536C1 (ru) * 2012-08-20 2014-01-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Производное амида салициловой кислоты, обладающее антибактериальной, противогрибковой и антилизоцимной активностью

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260321A (en) * 1984-11-12 1993-11-09 Sandoz Ltd. Use of 1,4-dihydropyridine derivatives and combinations thereof with calcitonins
US5733647A (en) * 1992-11-05 1998-03-31 Polymer Innovations, Inc. Insole
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
EP0993831B1 (en) * 1997-02-07 2008-01-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE60017888T2 (de) * 1999-04-05 2006-01-19 Emisphere Technologies, Inc. Dinatrium-salze, monohydrate und ethanol-solvate
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Also Published As

Publication number Publication date
JP4541884B2 (ja) 2010-09-08
ES2379949T3 (es) 2012-05-07
TW200403052A (en) 2004-03-01
BR0312712A (pt) 2005-04-26
JP2005535670A (ja) 2005-11-24
WO2004006907A1 (en) 2004-01-22
CA2492378A1 (en) 2004-01-22
US20120088833A1 (en) 2012-04-12
CN1668290B (zh) 2010-04-28
US8664211B2 (en) 2014-03-04
US20060106110A1 (en) 2006-05-18
CA2492378C (en) 2011-06-14
EP1556027A1 (en) 2005-07-27
CN1668290A (zh) 2005-09-14
PT1556027E (pt) 2012-04-10
EP1556027B1 (en) 2011-12-28
US20080280817A1 (en) 2008-11-13
ATE538782T1 (de) 2012-01-15

Similar Documents

Publication Publication Date Title
AU2003272590A1 (en) Method for ophtalmic administration of medicament
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
WO2007126964A3 (en) Kinase inhibitors
EG25822A (en) Quinolinyl-pyrrolopyrazoles
WO2003000343A3 (en) Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
AU2003267203A8 (en) Method for administering thermotherapy to prevent the growth of tumors
WO2004054505A3 (en) Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
GB0406282D0 (en) Therapeutic compounds
MXPA04010055A (es) Derivados de tioxantina como inhibidores de mieloperoxidasa.
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
PT1727551E (pt) Composição farmacêutica compreendendo um derivado de benzodiazepina e um inibidor da proteína de fusão do rsv
DE60322417D1 (en) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1,8-naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
ZA200603538B (en) P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
AU2003257473A1 (en) Modified amino acid for the inhibition of platelet aggregation
AU2003235798A1 (en) Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation
WO2001030331A3 (en) Therapeutic compositions including protein kinase c inhibitors
MXPA05009242A (es) Tratamiento de la diabetes tipo 1 con los inhibidores de la pde5.
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
GEP20063758B (en) Benzothia(Dia)Zine Derivatives and Method for Their Use as AMPA Modulators
AU2003286118A1 (en) Novel chelidonine derivatives, methods for the production thereof, and use thereof for producing pharmaceutical agents
WO2001030328A3 (de) Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von durch ischämischen zuständen bewirkten krankheiten
EP1526838B8 (de) Intravenös applizierbare, pharmazeutische darreichungsform
AU2003227524A1 (en) Use of bisphosphonic acid derivatives for the treatment of calcium phrophosphated deposition disease and dental treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase